Futura Medical (FUM) H2 2024 earnings summary

Executive summary

• Achieved maiden profit in 2024 with strong revenue growth and successful execution of strategic priorities, including expanding product launches and pipeline development.

• Eroxon, the lead product for erectile dysfunction, is now available in at least 15 countries, with plans to reach over 20 by end of 2025.

• Continued focus on launching in new markets, optimizing brand establishment, and leveraging commercial partnerships.

Financial highlights

• Reported revenues just under GBP 14 million for FY 2024, with about 50% from milestone payments and 50% from product sales and royalties.

• Gross profit reached GBP 9.7 million, with a blended gross margin of 70%.

• Profit after tax was GBP 1.3 million; adjusted profit after tax (excluding GBP 2 million non-cash share-based payments) was GBP 3.3 million.

• Ended the year with GBP 6.6 million in cash, supporting ongoing operations and R&D investments.

Outlook and guidance

• Expect Eroxon to be available in over 20 countries by end of 2025, with additional launches planned.

• Sales guidance revised downward; sales likely to be lower than initially forecast due to early-stage market dynamics and product effectiveness in younger demographics.

• Continued investment in pipeline products Eroxon Intense and WSD4000, with regulatory milestones targeted for 2025–2028.